Introduction {#Sec1}
============

Hepatocellular carcinoma (HCC) is the most frequent liver cancer and among the most lethal and prevalent malignancies in humans \[[@CR1]\]. Several risk factors are associated with the development of HCC. These include chronic infections with hepatitis viruses (HBV or HCV), exposure to aflatoxin-B1, polycystic aromatic hydrocarbons and nitrosamines, as well as alcoholic and non-alcoholic fatty liver disease \[[@CR2]\]. HCC can be triggered in experimental animal models with a single postnatal injection of the chemical carcinogen diethylnitrosamine (DEN) \[[@CR3]\]. The intense inflammatory response triggered by the hepatic injury leads to the immune surveillance of the damaged tissue \[[@CR4]\]. However, this response also further stimulates tumor development via compensatory hepatocyte proliferation \[[@CR5], [@CR6]\]. Apoptotic cell death is recognized as a crucial event in chemical-induced hepatocyte cell death and HCC development \[[@CR7]\]. Several BCL-2 family members have been implicated in hepatocarcinogenesis and in coupling apoptosis regulation and cell proliferation in unique ways \[[@CR8], [@CR9]\].

BCL-2-related ovarian killer (BOK) is a BCL-2 family member with a function difficult to elucidate \[[@CR10]\]. Early studies proposed that BOK may act as a BAX-like protein, based on sequence homology and since its over-expression induced cell death \[[@CR11], [@CR12]\]. To date, functional studies on mammalian forms of BOK have largely been restricted to over-expression systems. Interestingly, and in contrast to BAX and BAK, BOK localizes preferentially to the membranes of the endoplasmic reticulum (ER) and the Golgi apparatus, but only weakly to mitochondria. Furthermore, we and others \[[@CR13], [@CR14]\] have shown that significant amounts of BOK are also present in the nucleus of mouse and human cells, including primary mouse hepatocytes and mouse embryo fibroblasts \[[@CR15]\], as well as human non-small cell lung cancer cells \[[@CR16]\]. ER-localization of BOK is supported by its interaction with inositol-3-phosphate receptors (IP3R) \[[@CR17]\] and by its effect on Ca^2+^ homeostasis in neurons \[[@CR18]\]. BOK was recently described to be rapidly turned over by the ubiquitin/proteasome pathway \[[@CR19], [@CR20]\] and to act as a non-canonical effector of intrinsic apoptosis regulated by ER-associated degradation \[[@CR19]\]. Whereas no overt spontaneous phenotype was seen in three independently derived *Bok-*deficient mouse strains \[[@CR19], [@CR21], [@CR22]\], indirect indication for a physiological pro-apoptotic role of BOK was derived from analysis of *Bok* ^*-/-*^ *Bax* ^*-/-*^ females, which have an abnormally increased number of oocytes \[[@CR23]\] and from a further, modest increase in lymphocyte numbers in a *Bax* ^*-/-*^ *Bak* ^*-/-*^ hematopoietic system upon additional loss of *Bok* \[[@CR24], [@CR25]\]. Interestingly, BO*K* was identified in a genomic region that is relatively frequently deleted in human cancers \[[@CR26]\]. Loss of *Bok* did, however, not affect the outcome of *Eµ-myc* transgene-induced preB-/B-cell lymphoma in the mouse \[[@CR21]\]. The same study also showed that endogenous BOK levels are very low in lymphocytes, whereas generally BOK is widely expressed, with readily detectable protein expression levels in most tissues, particularly in reproductive organs, brain, and gastrointestinal tract, including liver \[[@CR15], [@CR21]\]. Of note, there is no indication for increased deletion of the *BOK* gene in human HCC according to The Cancer Genome Atlas (TCGA) database. Overall, the pathophysiological role of BOK remains elusive.

Here, we show that DEN treatment of mice results in an increased BOK expression in the liver and that BOK contributes to DEN-induced acute hepatocellular apoptosis. Induction of CHOP, PUMA, and BIM by DEN was decreased in *Bok* ^*-/-*^ mice, as was the oligomerization of BAX, supporting a pro-apoptotic role of BOK upstream of mitochondria. As a consequence of reduced liver damage and resulting compensatory proliferation in an inflammatory environment, the incidence of HCC was significantly reduced in *Bok* ^*-/-*^ mice compared to WT controls. Surprisingly, loss of BOK also resulted in smaller tumors, which correlated with reduced cellular proliferation of HCC both in vivo and in vitro, indicating that BOK does not only contribute to initial hepatocyte cell death but also affects cell cycle progression during hepatocarcinogenesis. Altogether, these data show that BOK plays a previously unrecognized role in the pathogenesis of liver disease.

Results {#Sec2}
=======

BOK contributes to chemical-induced acute liver damage and hepatocyte apoptosis {#Sec3}
-------------------------------------------------------------------------------

DEN is a potent alkylating agent inducing DNA damage and hepatocellular cell death upon conversion into alkyl-diazohydroxide by intrahepatocellular cytochrome P450 \[[@CR27]\]. In order to evaluate if DEN affects BOK expression levels we treated adult WT animals with DEN (100 mg/kg BW). We observed that DEN promoted a strong upregulation (16-fold and 19-fold after 1 and 3 days, respectively) of *Bok* mRNA in WT livers (Fig. [1a](#Fig1){ref-type="fig"}), indicating that *Bok* was transcriptionally induced. *Bok* induction was at least partially dependent on c-Jun N-terminal kinase (JNK) as it was significantly reduced by D-JNKI1 inhibitor at early time points (1 day), whereas *Bok* levels were not affected upon loss of p53 (Supplementary Fig. [S1](#MOESM1){ref-type="media"}). Importantly, BOK protein levels were also significantly increased after DEN challenge compared to controls (Fig. [2a](#Fig2){ref-type="fig"}). To test a potential pro-apoptotic role of BOK we compared DEN-induced acute liver damage in WT and *Bok* ^*-/-*^ animals. As shown in Fig. [1b](#Fig1){ref-type="fig"}, serum ALT levels were lower in *Bok* ^*-/-*^ animals 1 day after DEN exposure when compared to WT controls. TUNEL staining revealed less hepatocyte cell death in *Bok* ^*-/-*^ mice (Fig. [1](#Fig1){ref-type="fig"}c and [d](#Fig1){ref-type="fig"}). Proteolytic processing of procaspase-3 into its active form was detected in livers from treated WT mice but was reduced in *Bok* ^*-/-*^ mice (Fig. [1e](#Fig1){ref-type="fig"}) indicating that *Bok* ^*-/-*^ animals were partially protected against DEN-induced liver damage. Of note, CHOP and the pro-apoptotic BH3-only proteins PUMA and BIM were strongly induced by DEN in WT livers, but clearly less so in livers of *Bok* ^*-/-*^ mice (Fig. [2b and c](#Fig2){ref-type="fig"} and Supplementary Fig. [S2a](#MOESM1){ref-type="media"}). Taken together, these data indicate that DEN treatment induces BOK expression and that BOK contributes to DEN-mediated hepatocellular apoptosis upstream of CHOP, PUMA, and BIM. In support of a pro-apoptotic role of BOK upstream of mitochondrial permeabilization, we detected less activated BAX, as assessed by its oligomerization status, in livers from DEN-treated *Bok* ^*-/-*^ mice compared to WT controls (Supplementary Fig. [S2b](#MOESM1){ref-type="media"}).Fig. 1BOK contributes to DEN-induced liver damage. **a** *Bok* mRNA expression in the livers of WT and *Bok* ^*-/-*^ animals after DEN exposure. *Hprt* served as reference gene. Values represent the mean ± SD (*n* = 3 mice per group). **b** Serum ALT levels were determined in WT and *Bok* ^*-/-*^ mice after DEN exposure (100 mg/kg BW). Values represent mean ± SD. **c** Representative fluorescence micrographs of TUNEL staining and **d** quantification of TUNEL-positive cells in livers from WT and *Bok* ^*-/-*^ animals treated with DEN (100 mg/kg BW). Values represent the mean ± SD (*n* = 3 mice per group). **e** Quantitative western blot analysis using near-infrared fluorescence of activated caspase-3 in liver lysates from WT and *Bok* ^*-/-*^ animals 3 days after DEN (100 mg/kg) injection. Values represent the mean ± SD (*n* = 3 mice per group) Fig. 2BOK protein is increased in response to DEN and promotes induction of CHOP, BIM and PUMA. **a** Quantitative western blot analysis showing increase in BOK protein levels in WT animals treated with DEN (100 mg/kg). Lower band of BOK is due to alternative START codon \[[@CR20]\]. Values represent mean ± SD (*n* = 3--6 per group). Statistical analysis was performed by one-way ANOVA followed by a Tukey post-test analysis. **b** Induction of *Bim* and *Puma* mRNA by DEN (100 mg/kg) is decreased in livers of *Bok* ^*-/-*^ mice. *Gapdh* served as reference gene. Values are normalized to PBS controls and represent the mean ± SD (*n* = 3 mice per group). **c** Representative western blot data of liver lysates from DEN (100 mg/kg) treated WT and *Bok* ^*-/-*^ mice and quantification using near-infrared fluorescence. Values represent the mean ± SD (*n* = 6 mice per group)

Bok^-/-^ mice are partially protected from chemical-induced hepatocarcinogenesis {#Sec4}
--------------------------------------------------------------------------------

DEN is a widely accepted agent to induce hepatocarcinomas in mice \[[@CR3]\]. Acute cell death triggered by DEN promotes an inflammatory response that further stimulates tumor development \[[@CR5]\]. We observed that *Bok* ^*-/-*^ animals presented significantly reduced mRNA levels of the pro-inflammatory cytokines TNFα and IL-6 in their livers compared to WT controls after short-term exposure to DEN, and that leukocyte infiltration, which became evident at day 3 of treatment, seemed to correlate with the degree of liver damage (Supplementary Fig. [S3](#MOESM1){ref-type="media"}). We also noted that hepatocyte proliferation was decreased in *Bok* ^*-/-*^ livers compared to WT controls 10 days after DEN treatment (Supplementary Fig. [S4](#MOESM1){ref-type="media"}). Considering this, we sought to investigate how loss of BOK would affect DEN-induced hepatocarcinogenesis. Fifteen-day-old male WT and *Bok* ^-/-^ mice were injected with a single dose of DEN (25 mg/kg BW; a dose that also induced BOK and BOK-dependent liver damage in adult WT mice, see Supplementary Fig. [S5](#MOESM1){ref-type="media"}). At the endpoint of 9 months, macroscopic tumor development was observed in both genotypes (Fig. [3a](#Fig3){ref-type="fig"}). However, *Bok* ^*-/-*^ animals presented significantly (three times) fewer tumors than WT controls (Fig. [3b](#Fig3){ref-type="fig"}). Interestingly, a reduced average tumor size was also observed in *Bok* ^*-/-*^ animals (Fig. [3c](#Fig3){ref-type="fig"}). Blinded histopathological evaluation confirmed that the prevalence of histologically confirmed HCC is significantly reduced in *Bok* ^*-/-*^ mice (Fig. [3d](#Fig3){ref-type="fig"}) and that *Bok* ^*-/-*^ animals present a lower incidence of inflammation, ballooning and steatohepatitis, and less steatosis (Fig. [3e and f](#Fig3){ref-type="fig"}). Neither WT nor *Bok* ^*-/-*^ tumors or surrounding liver tissue showed increased signs of fibrosis (Supplementary Fig. [S6](#MOESM1){ref-type="media"}). Taken together, these data indicate that BOK contributes to chemical-induced hepatocarcinogenesis.Fig. 3BOK promotes chemical-induced hepatocarcinogenesis. **a** Gross liver tumor morphology and corresponding representative H&E-stained tumors in WT and *Bok* ^*-/-*^ animals 9 months after DEN treatment (25 mg/kg BW). **b** Quantification of liver tumors in WT and *Bok* ^*-/-*^ animals. Values represent the mean ± SD (WT *n* = 10; *Bok* ^*-/-*^ *n* = 13). **c** Average tumor size per group (diameter by caliper). **d** Quantification of histologically confirmed HCC. Values represent the mean ± SD (*n* = 10 per group; blindly evaluated and randomly selected). **e** H&E-stained sections of livers 9 months after DEN injection. Histopathological examination revealed that *Bok* ^*-/-*^ animals are less prone to inflammation, ballooning, and steatohepatitis and **f** show less steatosis in non-tumor areas. Values represent the mean ± SD (*n* = 10 per group; blindly evaluated and randomly selected)

BOK deficiency limits cell proliferation {#Sec5}
----------------------------------------

Some BCL-2 family members are known to influence cell proliferation in addition to cell survival \[[@CR28]\]. *Bok* ^*-/-*^ animals presented not only fewer, but also smaller tumors than WT controls. Considering this, we compared the proliferative rate in liver tumors from WT and *Bok* ^*-/-*^ animals 9 months after DEN treatment. Immunohistochemical quantification of the proliferation marker Ki-67 showed that tumors from *Bok* ^*-/-*^ animals presented three times fewer Ki-67 positive cells than tumors from WT controls (Fig. [4a and b](#Fig4){ref-type="fig"}). To evaluate if BOK deficiency could directly affect cell proliferation in vitro, we compared proliferation rates of immortalized human hepatocytes (IHH) and human HCC cell lines upon downregulation of *BOK*. As shown in Fig. [4c](#Fig4){ref-type="fig"} (and Supplementary Fig. [S7](#MOESM1){ref-type="media"}), IHH cells and HepG2 human hepatocarcinoma cells with CRISPR/Cas9-mediated *BOK* disruption, or the HCC cell line HLE upon shRNA-mediated *BOK* downregulation, proliferated significantly slower than controls. Growth curves and colony formation assays of immortalized mouse embryo fibroblasts (SV40 MEF) isolated from WT and *Bok* ^*-/-*^ mice further confirmed that loss of BOK can result in significantly slower proliferation (Fig. [4](#Fig4){ref-type="fig"} [d](#Fig4){ref-type="fig"}). Importantly, re-expression of BOK in *Bok* ^*-/-*^ MEF fully rescued this proliferation defect, proving that it is a BOK-specific effect (Fig. [4d](#Fig4){ref-type="fig"}). However, re-expression of a BOK mutant, BOK(L72A,R73A,L74A), in which the reported nuclear export signal (NES) \[[@CR13]\] was destroyed, failed to rescue the growth defect in *Bok* ^*-/-*^ MEF (Fig. [4e](#Fig4){ref-type="fig"}). The same mutant also showed a reduced localization in purified nuclear fractions and consequently accumulated in the cytoplasm (Fig. [4f](#Fig4){ref-type="fig"}). Given that the NES of BOK is situated within its BH3-domain, these data imply that BOK requires either its BH3 domain and/or a nuclear localization to drive proliferation. Nuclear localization of BOK was confirmed in HLE cells and, interestingly, cytoplasmic-to-nuclear ratio of BOK likewise increased upon knockdown of *BOK* (Supplementary Fig. [S7g](#MOESM1){ref-type="media"}). Loss of BOK also negatively affected cell growth of non-transformed bone marrow-derived mast cells (Supplementary Fig. [S8](#MOESM1){ref-type="media"}). Taken together, these data indicate that BOK plays a role in controlling cellular proliferation in vitro and in vivo.Fig. 4Loss of BOK affects cellular proliferation. **a** Immunohistochemistry showing Ki-67 staining in HCC tumors from WT and *Bok* ^*-/-*^ animals. **b** Quantification of Ki-67 positive cells in HCC tumors from WT and *Bok* ^*-/-*^ mice. Values represent the mean ± SD (*n* = 3 mice per group). **c** Growth curves and colony formation assay of IHH subclones with CRISPR/Cas9-mediated gene disruption of *BOK*. **d** Growth curves and colony formation assay of SV40 MEF derived from three different WT and *Bok* ^*-/-*^ embryos, each. Stable re-expression of BOK in *Bok* ^*-/-*^ SV40 MEF rescues the growth defect. **e** Stable re-expression of a BOK mutant, BOK(AAA), in which the predicted NES sequence within the BH3 domain has been mutated (L72A,R73A,L74A), fails to rescue the growth defect in *Bok* ^*-/-*^ SV40 MEF. Values represent the mean ± SD (*n* = 3). **f** BOK(AAA) accumulates in the cytoplasm compared to wildtype BOK. *T* total, *C* cytoplasmic fraction, *N* nuclear fraction. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.005, \*\*\*\**p* \< 0.001

Loss of BOK promotes induction of cyclin kinase inhibitors p19^ink4d^ and p21^cip1^ {#Sec6}
-----------------------------------------------------------------------------------

To gain further insight into the role of BOK in cell proliferation, expression profiling of 88 cell cycle related genes was performed with IHH and two human HCC lines, in which *BOK* was deleted or downregulated. Only few genes showed consistent changes in expression levels among the three different cell lines. The genes upregulated in *BOK-*deficient cells were linked to cell cycle arrest and DNA damage response, including cyclin kinase inhibitor *CDKN2D* (p19^INK4d^), *BCL-2*, *TP53*, *RPA3*, *GADD45A-6*, *CDK5*, whereas only *CCNA2*, encoding for cyclin A2, was consistently downregulated (Supplementary Fig. [S9](#MOESM1){ref-type="media"}). To better understand the impact of *BOK* deletion on *CDKN2D* expression, we evaluated p19^INK4d^ protein expression in livers from short-term DEN treated WT and *Bok* ^*-/-*^ animals. Of note, p19^INK4d^ steady-state protein levels were, on average, two times higher in livers from *Bok* ^*-/-*^ animals compared to WT controls (Fig. [5a](#Fig5){ref-type="fig"}). Whereas p19^INK4d^ levels increased upon DEN treatment in WT livers, they remained unchanged in *Bok* ^*-/-*^ livers. Interestingly, p19^INK4d^ was differentially distributed in hepatocytes of WT and *Bok* ^*-/-*^ animals. Whereas p19^INK4d^ was localized both in the cytoplasm and in the nucleus of WT hepatocytes, it was found predominantly in the nucleus of *Bok* ^*-/-*^ hepatocytes (Fig. [5b](#Fig5){ref-type="fig"}). In the tumors of DEN-treated WT animals p19^INK4d^ expression was reduced compared to adjacent 'healthy' liver tissue, whereas the tumors of *Bok* ^*-/-*^ animals expressed readily detectable levels of p19^INK4d^ in both HCC tumors and surrounding 'healthy' liver tissue (Fig. [5c](#Fig5){ref-type="fig"}). We also observed that BOK repression affected expression of another cyclin kinase inhibitor, p21^cip1^ (Fig. [5d](#Fig5){ref-type="fig"}). p21^cip1^ was strongly expressed and mainly localized in the nuclei of hepatocytes from *Bok* ^*-/-*^ mice, while it was hardly detectable in WT hepatocytes (Fig. [5e](#Fig5){ref-type="fig"}). In addition, tumors and adjacent tissue from *Bok* ^*-/-*^ animals were positive for p21^cip1^, whereas tumors from WT animals were consistently negative (Fig. [5f](#Fig5){ref-type="fig"}). Using isogenic HCT-116 colorectal carcinoma cells proficient or deficient for p53 or p21, respectively, we observed that the growth defect inflicted upon downregulation of *BOK* was dependent on p21 and p53 (Supplementary Fig. [S10](#MOESM1){ref-type="media"}). Taken together, these data indicate that BOK depletion affects the expression of genes implicated in cell cycle arrest, and remarkably, impacts on the expression pattern of p19^INK4d^ and p21^cip1^ in hepatocytes and HCC cells.Fig. 5Loss of BOK induces p19^INK4d^ and p21^cip1^ expression. **a** Quantitative western blot analysis of p19^INK4d^ expression using near-infrared fluorescence of liver extracts from WT and *Bok* ^*-/-*^ animals treated with DEN (100 mg/kg BW). Values represent the mean ± SD (*n* = 4 mice per group). **b** Immunohistochemistry of liver sections showing cytoplasmic and nuclear localization of p19^INK4d^ in untreated WT animals and predominantly nuclear localization in *Bok* ^*-/-*^ livers. **c** Immunohistochemistry of liver sections indicating p19^INK4d^ staining (red) in tumors from WT and *Bok* ^*-/-*^ animals. Counterstain was performed with Mayer's Hematoxilin. **d** Quantitative western blot analysis using near-infrared fluorescence of p21^cip1^ expression of liver extracts from WT and *Bok* ^*-/-*^ animals treated with DEN (100 mg/kg BW). Values represent the mean ± SD (*n* = 4 mice per group). **e** Immunohistochemistry of liver sections showing negative staining for p21^cip1^ in untreated WT animals and predominantly nuclear localization in *Bok* ^*-/-*^ mice (red). **f** Immunohistochemistry of liver sections indicating p21^cip1^ negative staining in tumors from WT mice and positive staining for *Bok* ^*-/-*^ tumors (red). *T* tumor area, *NT* non-tumor area. At least two tumors/animal and 3--4 animals per genotype were used for quantifications in (**c**) and (**f**)

Discussion {#Sec7}
==========

Despite its discovery 20 years ago the physiological and pathophysiological relevance of BOK remains largely unknown. BOK induces apoptosis when over-expressed and it shows best amino acid sequence homology to BAK and BAK. However, it is currently controversially discussed whether BOK is a genuine pro-apoptotic BCL-2 family member and whether it can induce intrinsic apoptosis independently of BAX/BAK \[[@CR15], [@CR18], [@CR19], [@CR22], [@CR29]--[@CR31]\]. What has emerged is that BOK is widely expressed and readily detectable at the endogenous protein level in most cell types, maybe with the exception of the hematopoietic system \[[@CR21]\], and that in contrast to BAX and BAK, most of the cytoplasmic BOK localizes to the ER; furthermore, BOK is also prominently found in nuclear fractions \[[@CR13]--[@CR16]\].

BOK is consistently expressed throughout the gastrointestinal tract, with high levels in the liver \[[@CR21]\]. Here we show that BOK is strongly induced at the mRNA and protein levels upon short-term treatment with DEN and, importantly, that BOK promotes DEN-induced liver damage and associated inflammation. Induction of *Bok* mRNA seems to be at least partially mediated by JNK, but independent of p53, which is in analogy to a report for the induction of *Puma* by DEN \[[@CR8]\]. As shown by Das and colleagues using conditional *Jnk1/2*-deficient mice, the role of JNK is ambiguous, with different effects on HCC development in hepatocytes or non-parenchymal cells \[[@CR32]\]. Our study was performed in a constitutive *Bok*-deficient strain, which limits the conclusions to some extents. Conditional deletion of *Bok* (i.e. hepatocyte-specific and/or nonparenchymal-specific deletion) will be necessary to demonstrate the contribution of BOK in hepatocytes or non-parenchymal cells, respectively, in the DEN model and, importantly, to address a possible role of liver resident (or recruited) leukocytes therein.

Our findings show that BOK contributes to chemical-induced hepatocellular apoptosis (see Fig. [6](#Fig6){ref-type="fig"} for a schematic model). In line with its localization at the ER and our previous observation that over-expressed BOK induces BIM and PUMA \[[@CR15]\], we found that BOK acts upstream of CHOP, BIM, and PUMA induction in response to DEN. A connection between BOK and CHOP has been reported earlier, albeit in a different context \[[@CR22]\]. Overall, these data support a pro-apoptotic role of BOK upstream of mitochondrial apoptotic events mediated by BAX/BAK, and this was further underlined by our finding that BAX oligomerization, which we used as a readout for its activation status, is reduced in livers of short-term DEN-treated *Bok* ^*-/-*^ mice compared to WT controls.Fig. 6Schematic model of how BOK contributes to DEN-induced HCC. BOK levels in the liver are increased in the short-term response to DEN and BOK contributes to liver damage upstream of BIM and PUMA induction. As a consequence of reduced cell death, associated inflammation and compensatory proliferation, *Bok* ^*-/-*^ mice develop fewer HCC tumors in the long term. Additionally, BOK has a likely cell death-independent function of positively modulating cellular proliferation of HCC cells, resulting in smaller tumors in *Bok* ^*-/-*^ mice

Reduction of apoptosis and, consequently, inflammation and compensatory hepatocellular proliferation is strongly associated with reduced HCC development \[[@CR5]--[@CR7]\]. In line with these observations, we report that at the endpoint of 9 months after DEN exposure *Bok* ^*-/-*^ animals were partially protected from HCC development, displaying significantly reduced tumor numbers, as well as smaller tumors. Interestingly, *BOK* was identified in a genomic region that undergoes relative frequent deletion in human cancers, making *BOK* one of the most often deleted members among the pro-apoptotic BCL-2 family \[[@CR26]\]. However, according to The Cancer Genome Atlas (TCGA) database, the human *BOK* locus is rarely deleted in primary liver cancer. Likewise, *BOK* mRNA levels do not seem to be decreased in human HCC based on publicly available databases. Information on the BOK protein status in human HCC specimens is currently missing. Nevertheless, we observed that established HCC in WT mice expressed comparable levels of BOK protein compared to healthy liver (data not shown). This apparent lack of selection pressure to lose BOK during liver cancerogenesis is in line with our finding that BOK promotes HCC. Our findings support other reports on pro-apoptotic BCL-2 proteins promoting HCC, such as PUMA \[[@CR8]\] or BID \[[@CR9]\]. Inversely, loss of anti-apoptotic MCL-1 in hepatocytes was shown to trigger spontaneous apoptosis and to promote development of HCC \[[@CR33]\]. Along the same line, over-expression of BCL-2 was shown to inhibit SV40 large T antigen transgene-induced liver cancer development \[[@CR34]\]. Interestingly, loss of *Puma* has also been implicated with decreased tumorigenesis in a radiation-induced thymic lymphoma model \[[@CR35], [@CR36]\]. Collectively, these findings suggest that damage-induced cell death can promote tumour development by causing enhanced proliferation of progenitor cells, which due to their rapid proliferation may sustain oncogenic DNA lesions.

Following our observation that *Bok* ^*-/-*^ mice also presented smaller tumors, we demonstrate that loss of BOK negatively affects cellular proliferation. Tumors from *Bok* ^*-/-*^ animals proliferated slower than tumors form WT mice. In addition, two human HCC lines, IHH, MEF, and non-transformed mast cells proliferated significantly slower upon loss of BOK. This result points towards an important role of BOK that may be independent of its role in cell death regulation. Based on these findings that link BOK to the regulation of HCC proliferation, targeting BOK in established HCC expressing high levels of BOK may be beneficial in slowing tumor growth.

A nuclear localization of BOK has been reported by several groups and linked to proliferation in trophoblasts during early placentation \[[@CR13], [@CR14]\]. In support of this, we have previously shown that significant amounts of total BOK are found in purified nuclear fractions of MEF, mouse primary hepatocytes and in a panel of human non-small cell lung carcinoma cells lines, and that loss of BOK decreases cell growth in the latter \[[@CR15], [@CR16]\]. Here we demonstrate that this is also true for HCC cells, in which loss of BOK resulted in reduced proliferative capacity in vitro and in vivo. Interestingly, downregulation of *BOK* in HLE cells resulted also in an increased cytoplasmic-to-nuclear BOK ratio. It is therefore an interesting hypothesis to segregate a role of cytoplasmic BOK in cell death regulation from a putative role of nuclear BOK in proliferation. Importantly, reduction of BOK by RNA interference or gene editing by CRISPR/Cas9, resulted in induction of several genes implicated with cell cycle arrest: *BCL-2*, recognized as cell cycle regulator and able to inhibit liver carcinogenesis upon over-expression in mice \[[@CR37]\]; *CDK5*, which is essential for neuronal cell cycle arrest and differentiation \[[@CR38]\]; and p19^INK4d^. p19^INK4d^ was described to improve DNA repair, decrease apoptosis and increase neuronal survival in conditions of genotoxic stress \[[@CR39]\]. Additionally, p19^INK4d^ is normally localized both in the nucleus and cytoplasm \[[@CR40]\]. We confirmed this cellular distribution in livers of WT animals. Intriguingly, however, the expression of p19^INK4d^ in *Bok* ^*-/-*^ hepatocytes was predominantly nuclear, similar to the distribution pattern reported for cells treated with UV radiation \[[@CR41]\]. We also show that p19^INK4d^ expression was strongly reduced in DEN-induced HCC tumor tissue of WT mice whereas it remained detectable in tumors of *Bok* ^*-/-*^ animals. This result is in line with a previous report showing that p19^INK4d^ expression is frequently lost in HCC, actually proposing it as a new prognostic marker \[[@CR42]\]. Like p19^INK4d^, p21^cip1^, another cyclin kinase inhibitor with a recognized role both in normal hepatocytes and in hepatocarcinogenesis \[[@CR43], [@CR44]\], was found to be upregulated in BOK-deficient tumors. We accordingly found that loss of the proliferative capacity in the absence of BOK depends on p21 and p53 in HCT-116 cells. Furthermore, we identified the previously reported NES sequence of BOK \[[@CR13]\], which intriguingly is located within its BH3 domain, as crucial sequence to drive proliferation. In contrast to Bartholomeusz et al., however, we found that BOK with a mutated NES accumulates in the cytoplasm rather than in the nucleus. The underlying reason for this discrepancy is currently not clear and warrants further investigation. Taken together, our data indicate that BOK either requires its BH3 domain and/or a nuclear localization in order to affect cellular proliferation. Interestingly, p21^cip1^ and p19^INK4d^ activation may also be involved in senescence induction, which is another well-described tumor suppressive mechanism through which pre-malignant senescent hepatocytes are subjected to immune cell-mediated clearance \[[@CR4]\]. Even though mouse leukocytes express very low levels of BOK \[[@CR15], [@CR21]\], generation of a conditional *Bok*-deficient mouse model is necessary to address a specific role of BOK in immune cells in DEN-induced HCC.

In summary, we show that BOK is induced by DEN and that BOK contributes to DEN-induced hepatocellular apoptosis and subsequent hepatocarcinogenesis. Furthermore, loss of BOK results in reduced proliferation of HCC cells in vitro and in vivo, correlating with an upregulation of genes enrolled in cell cycle arrest with a recognized role in hepatocarcinogenesis. Considering this, it is reasonable to propose that strategies aiming to prevent BOK induction or activation during liver injury may have a favorable impact on HCC development and progression.

Materials and methods {#Sec8}
=====================

Reagents {#Sec9}
--------

IMDM, RPMI 1640 medium, and DEN were purchased from Sigma-Aldrich (Buchs, CH). DMEM/GlutaMAX, penicillin/streptomycin, [l]{.smallcaps}-glutamine, and trypsin solution were purchased from Thermo Fisher Scientific. Fetal calf serum (FCS, Sera Pro, ultra-low endotoxin) was purchased from Pan Biotech (Aidenbach, DE).

Mice and treatment {#Sec10}
------------------

*Bok* ^*-/-*^ mice were generated on a C57BL/6 inbred genetic background as previously described \[[@CR21]\] and were used along with corresponding age-matched and sex-matched WT animals. All mice were maintained in pathogen-free conditions with free access to food and water. Experiments were approved by the Animal Experimentation Review Board of the Canton of Bern, Switzerland (BE15/13). All mice received humane care according to the criteria outlined in the *Guide for Care and Use of Laboratory Animals* (National Institutes of Health publications 86-23, revised 1985). For DEN-induced HCC, DEN (25 mg/kg body weight) was injected intraperitoneally into 14 days old males. Mice were sacrificed after 9 months on the standard diet (Complete Food for Mice and Rats, No. 3432, Kliba Natag, Kaiseraugust, CH). Tumors in each liver lobe were counted and measured with a caliper. Tumor and non-tumor tissue was collected and quickly processed for histological, immunochemical, and biochemical analyses. Acute effects of DEN were studied in adult mice injected intraperitoneally with 100 mg/kg DEN and sacrificed after 1, 3, and 10 days, respectively.

Alanine aminotransferase (ALT) measurement {#Sec11}
------------------------------------------

Serum values of ALT were measured using the ALT Enzymatic Assay according to the manufacturer's instructions (Bioo Scientific, Austin, TX, USA).

Histology and histopathology {#Sec12}
----------------------------

Freshly dissected liver samples were fixed in 3.7% formaldehyde for 24 h, embedded in paraffin and 4 μm tissue sections stained with hematoxylin and eosin or processed for immunohistochemistry. Histopathological evaluation was performed blindly by a pathologist (M.M.).

Immunoblotting {#Sec13}
--------------

Details on sample preparation and SDS-PAGE can be found in the [Online Supplementary Material](#MOESM1){ref-type="media"}. Immunoprobing was performed with the following antibodies: mouse anti-tubulin (B-5-1-2; Sigma-Aldrich); rabbit anti-p21 (C-19; sc-397) and rabbit anti-CHOP (B-3) (Santa Cruz Biotechnologies); rabbit anti-cleaved caspase-3(D175) (5A1E) and rabbit anti-PUMA (\#7467) from Cell Signaling Technology; rat anti-BIM (3C5, Enzo Life Sciences); and rabbit anti-p19 INK4d (ab102842, Abcam). Rabbit monoclonal anti-BOK, RabMab BOK-1-5 \[[@CR15]\]. IRDye^®^ 800CW and 600CW near-infrared fluorochrome-conjugated secondary antibodies were purchased from LI-COR Biotechnology (Bad Homburg, DE). Quantitative western blot analysis was performed using an Odyssey Fc digital imaging system from LI-COR Biotechnology. Alternatively, horseradish peroxidase-coupled secondary antibodies (Jackson ImmunoResearch Europe Ltd.) were used and signals detected on an Odyssey Fc system by enhanced chemiluminescence (Luminata Forte, Merck Millipore). Data was quantified using Image Studio 3.1.4 software (LI-COR).

Cytoplasmic/nuclear fractionation {#Sec14}
---------------------------------

Cytoplasmic and nuclear fractions were prepared according to \[[@CR45]\] with some modifications. Briefly 3.5 × 10^6^ cells were incubated in 0.5 ml F1 buffer (20 mM Tris pH 7.6, 50 mM β-mercaptoethanol, 0.1 mM EDTA, 2 mM MgCl~2~, plus protease inhibitor cocktail) for 2 min at RT and 10 min on ice. Fifty microliters of 10% NP-40 were added and cells lysed by passing 3× through a 21 G needle. Lysate was centrifuged at 600 × *g* for 5 min at 4 °C and supernatant collected as cytoplasmic (C) fraction. Pellet was washed 3× in F1 buffer containing 1% NP-40 and processed as nuclear (N) fraction.

Immunofluorescence and immunohistochemistry {#Sec15}
-------------------------------------------

Immunostaining was performed after deparaffinization and rehydratation through graded alcohol. Antigen retrieval was performed in Dako Target Retrieval solution pH 6.0 (Dako, Baar, CH) using an electric pressure cooker (2100 Retriever, Aptum, Southampton, UK). Immunofluorescence was performed with the following primary antibody incubated overnight at 4 °C: rabbit anti-Ki-67 (SP6, Thermo Fisher Scientific) diluted in Dako Real^TM^ antibody diluent. Incubation with Alexa Fluor 488-conjugated IgG F(ab'2) secondary antibody (Thermo Fisher Scientific) was performed at RT for 1 h. Nuclear DNA was counterstained with Prolong Gold antifade reagent containing DAPI (Thermo Fisher Scientific). Immunohistochemistry was performed with the following primary antibodies: rabbit anti-p21 (C-19) (sc-397, Santa Cruz Biotechnologies), and rabbit anti-p19 INK4d (ab102842, Abcam). Staining was performed with Dako Envision^TM^ System-HRP specific for rabbit primary antibodies following the manufacturer's instructions. Staining was evaluated by Image-Pro Plus software (Media Cybernetics) and the area was analyzed by the count and size tool with hue saturation intensity (HSI) mode.

Cell death was evaluated by TUNEL staining following the manufacturer's instructions (In Situ Cell Death Detection Kit, Fluorescein, Roche Diagnostics). Images were acquired using a Zeiss Observer Z.1 fluorescence microscope connected to a Axiocam 506 digital color camera and using the ZEN pro 2012 (blue edition) software (Zeiss, Feldbach, CH). The percentage of Ki-67 and TUNEL positive cells was determined by counting at least 900 nuclei per condition.

RNA isolation and quantitative RT-PCR (qPCR) {#Sec16}
--------------------------------------------

Total RNA was extracted from liver samples with SV total RNA isolation system (Promega, Wallisellen, CH). One microgram of RNA was reverse-transcribed using oligo(dT) primer and M-MLV reverse transcriptase according to the manufacturer's instructions (Promega). qPCR reaction was performed using HOT FIREPol 'EvaGreen' qPCR Mix Plus (Solis Biodyne, Tartu, EST) on a Real-Time PCR detection system (CFX Connect^TM^, Bio-Rad). Mouse *Hprt* or *Gapdh* mRNA were used as reference genes. For primer sequences see Supplementary Table [S1](#MOESM1){ref-type="media"}.

Statistical analysis {#Sec17}
--------------------

Statistical analysis was performed using Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). Data are presented as means ± standard deviation (SD). Unless otherwise stated, statistical significance was calculated using the Student *t*-test or using a non-parametric Mann--Whitney test for samples not following normal distribution with homogenous variances. *P* \< 0.05 was considered significant.
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